<DOC>
	<DOC>NCT00977782</DOC>
	<brief_summary>This study will assess the safety, tolerability, and pharmacokinetics in AML and high risk MDS patients with either wild type or mutated FLT3 using PKC412 with intra-patient dose escalation.</brief_summary>
	<brief_title>Open-label Multicenter Study of PKC412 in Pts With AML and MDS With Either Wild-type or Mutated FLT3</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>4'-N-benzoylstaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>Patients with AML who are not candidates for myelosuppressive chemotherapy or AML who have relapsed disease or refractory to standard therapy and not likely to require cytoreductive therapy within one month, or MDS subtypes RAEB, RAEBT or CMML Patients with a wild type or mutated FLT3 documented within 14 days prior to start of study who have not previously received a FLT3 inhibitor. Patients with a WHO performance status of 0 to 2 with a life expectancy of at least 3 months Patients who had prior allergenic, syngeneic, or autologous bone marrow transplant or stem cell transplant less than 2 months previously. Female patients who are pregnant or breast feeding or adults of childbearing age not employing an effective method of birth control Concurrent severe and/or uncontrolled medical or psychiatric condition which may interfere with the completion of the study Impairment of GI function or GI disease that may significant alter the absorption of PKC412 Patients who had more than 2 prior regimens for their current relapsed or current primary refractory disease. Uncontrolled active infection Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>FLT3</keyword>
	<keyword>midostaurin</keyword>
	<keyword>wild type FLT3</keyword>
	<keyword>mutated FLT3</keyword>
</DOC>